Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

MAb-based immunosuppressant supports crucial diabetes cell transplants

Key Takeaway: The article discusses a monoclonal antibody (MAb)-based immunosuppressant that supports crucial diabetes cell transplants. This innovative treatment aims to improve transplant success rates and patient outcomes. The approach highlights the potential for transforming lives through effective organ transplantation. The advancements in immunosuppression are significant for diabetes patients requiring cell transplants.
Price reaction · baseline $3.465 (2026-04-27T19:58:00.000Z) · hit during market hours · 1 other ELDN headline(s) in the window, move may be shared
day 0 close · peak
-0.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • MAb-based immunosuppressant shows promise in diabetes cell transplants.
  • Potential to transform lives through successful organ transplants.
  • Innovative approach in immunosuppression could enhance transplant outcomes.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is the role of the MAb-based immunosuppressant?

The MAb-based immunosuppressant supports diabetes cell transplants, improving their success.

How does the MAb treatment benefit patients?

It enhances transplant outcomes, potentially transforming lives for diabetes patients.

What type of patients can benefit from this treatment?

Patients requiring cell transplants for diabetes can benefit from this innovative approach.

Last updated: Apr 27, 2026